Research programme: mRNA based vaccines - CureVac

Drug Profile

Research programme: mRNA based vaccines - CureVac

Alternative Names: RNActive® cancer immunotherapy; RNActive® infectious disease vaccines; RNActive® prophylactic vaccines

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureVac
  • Class Antineoplastics; Cancer vaccines; Influenza A vaccines; RNA vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections
  • Research Cancer; HIV infections; Rotavirus infections
  • No development reported Infections; Influenza A virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in Germany (Intradermal, Injection)
  • 20 Jul 2017 The European Patent Office grants a Notice of Allowance for a patent application (EP 2 958 588) for Cancer and Infectious diseases
  • 20 Jul 2017 Early research in Cancer in Germany (unspecified route) before July 2017 (CureVac Pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top